Crystalline norpsilocin compounds
AssigneeCaamtech, Inc.
InventorAndrew R. Chadeayne
Life of this patent
Estimating the term…
Abstract
The disclosure relates to norpsilocin compounds, compositions containing those crystalline compounds, and methods of treatment using them. The norpsilocin compounds include crystalline 4-hydroxy-N-methyltryptamine (“crystalline 4-HO-NMT” or “crystalline norpsilocin freebase”), crystalline 4-hydroxy-N-methyltryptammonium fumarate (“crystalline norpsilocin fumarate”), and 4-hydroxy-N-methyltryptammonium fumarate (“norpsilocin fumarate”) and their compositions and uses.
Claims11
A composition comprising crystalline 4-hydroxy-N-methyltryptammonium fumarate (norpsilocin fumarate) and an excipient,
- wherein crystalline norpsilocin fumarate is characterized by:
- a triclinic, P1 crystal system space group at a temperature of about 297 K;
- unit cell dimensions a=7.7363 (10) Å, b=9.7146 (12) Å, c=9.7854 (13) Å, α=105.524 (4)°, β=110.554 (4)°, and γ=97.167 (4)°;
- an XRPD having peaks at 11.5, 13.9, and 16.2°2θ±0.2° 2θ;
- or
- an XRPD pattern substantially similar to FIG. 7.
A composition comprising crystalline 4-hydroxy-N-methyltryptammonium fumarate (norpsilocin fumarate) and a second component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) one or two purified cannabinoids and (d) a purified terpene,
- wherein crystalline norpsilocin fumarate is characterized by:
- a triclinic, P1 crystal system space group at a temperature of about 297 K;
- unit cell dimensions a=7.7363 (10) Å, b=9.7146 (12) Å, c=9.7854 (13) Å, α=105.524 (4)°, β=110.554 (4)°, and γ=97.167 (4)°;
- an XRPD having peaks at 11.5, 13.9, and 16.2°2θ±0.2° 2θ;
- or
- an XRPD pattern substantially similar to FIG. 7.
4-hydroxy-N-methyltryptammonium fumarate (norpsilocin fumarate).
Dependencies are inferred from the claim text.